TUNICRIS-julkaisut - Trepo

Viitteet 1-1 / 1

Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Auranen, Annika; Powell, Matthew A.; Sukhin, Vladyslav; Landrum, Lisa M.; Ronzino, Graziana; Buscema, Joseph; Bauerschlag, Dirk; Lalisang, Roy; Bender, David; Gilbert, Lucy; Armstrong, Amy; Safra, Tamar; Nevadunsky, Nicole; Sebastianelli, Alexandra; Slomovitz, Brian; Ring, Kari; Coleman, Robert; Podzielinski, Iwona; Stuckey, Ashley; Teneriello, Michael; Gill, Sarah; Pothuri, Bhavana; Willmott, Lyndsay; Sharma, Sudarshan; Dabrowski, Christine; Antony, Grace; Stevens, Shadi; Mirza, Mansoor Raza; Fleming, Evelyn (2024)
article

Background: In Part 1 of the phase III RUBY trial (NCT03981796) in patients with primary advanced or recurrent endometrial cancer (EC), dostarlimab plus carboplatin–paclitaxel (CP) significantly improved progression-free ...